LIVE WEBINAR: Cellular Time Travel. Determine Today’s Transcriptome, Study Tomorrow’s Response
Join Cytosurge and Lexogen for an exclusive webinar showcasing breakthrough live-cell sequencing (Live-seq), the first end-to-end commercial live-cell sequencing workflow.
Live-seq is a radically different RNA-seq approach that uses subcellular biopsies to capture the full transcriptome from living cells – directly from within their culture dish. Just as doctors biopsy patients, we do it on cells – then track the same cell over time!
Live-seq reveals cause-and-effect relationships about individual cellular mechanisms with incredible ease: measure how and why cells respond to treatments, understand heterogeneity at unprecedented resolution, and uncover insights that constitute actionable leads for therapeutics and bioprocess optimization.
Come see how we made Live-seq easy to onboard and ready to deliver actionable molecular insights!
Can’t attend live? Sign up now to get the recording and resources afterward.
Agenda (20–25 min + 15 min Q&A) – 3:00 PM CET / 10:00 AM EDT (New York):
- Part 1: Live-seq in Practice
- Ludovica Rizzo, PhD (Applications Services Manager, Cytosurge), introduces Live-seq and demos the integrated workflow: FluidFM OMNIUM sampling + LUTHOR HD library prep.
- Part 2: Sensitivity That Changes the Game
- Filippo Passardi, PhD (Product Manager, Lexogen), explains how LUTHOR HD’s RNA-amplification chemistry enables ultra-low-input profiling, redefining less-than-cell and single-cell RNA-seq.
- Part 3: From Insight to Action
- Dr. Rizzo will showcase case studies and practical steps: feasibility, proof of principle for selected projects, and next steps to adopt Live-seq.
- Part 4: Live Q&A
Who should attend:
Industry Scientists – from pharma, biotech, and clinical research.
Academic Researchers & PIs – in cell biology, genomics, biomedical sciences, and single-cell technologies.
Lab Managers & Enthusiasts – evaluating workflows or interested in cellular behavior at the molecular level.
- Cytosurge Contact: Erica Fiorini, PhD, 📧 [email protected]
- Lexogen Contact: Amra Dedic 📧 [email protected]
Live-seq represents the world's first commercial end-to-end workflow for longitudinal, non-destructive cell sequencing. Developed through a year of collaboration between Cytosurge and Lexogen, this technology enables researchers to repeatedly sequence RNA from the same living cells, revealing causally-linked molecular and phenotypic data that was previously impossible to obtain. Validated in Nature (2022), Live-seq is now accessible to labs worldwide.
Resources: Shared Application Note (2024), Apply for the Live-seq Access Program
Register now!